According to Reuters, the US Food and Drug Administration has approved a rare blood cancer drug called Besponsa.
The drug was produced by big pharma company Pfizer Inc. Besponsa will be used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL).
This type of cancer causes bone marrow to produce too many B-Cell lymphocytes, an immature white blood cell.
Besponsa is a targeted therapy that binds to B-cell ALL cancer cells that expresses the CD22 antigen, blocking the growth of cancer cells.
When Sofia Smith stood on her school’s stage to say goodbye to her long blonde hair last month, eyes full of tears, she never imagined the international attention she would receive.
The nine-year-old had shaved her head to raise more than $20,000 dollars in support of Calgary charity Kids Cancer Care in Canada in solidarity with her older brother Rand, who had been diagnosed with cancer earlier just a few months before.
“I was thinking about how many lives I’ve just changed and how it can change my brother’s life,” Smith said shortly after the event.